BioLife Solutions Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

BioLife Solutions wird ein jährliches Gewinn- und Umsatzwachstum von 67.7% bzw. 14.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 68.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -7.4% betragen.

Wichtige Informationen

67.7%

Wachstumsrate der Gewinne

68.4%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	16.2%
Wachstumsrate der Einnahmen	14.9%
Zukünftige Eigenkapitalrendite	-7.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	17 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Jun 20

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Jun 05

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

May 14

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

May 13

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

May 11

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10

BioLife: What The Future Holds

Oct 19

BioLife Solutions COO Roderick de Greef to retire

Oct 03

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Sep 27

BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M

Aug 09

BioLife Solutions: Sell-Side Posture Overly Optimistic, Rate Neutral

Jul 29

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Jun 15

BioLife: Can This Company Successfully Turn Around?

Apr 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BLFS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	156	6	9	22	3
12/31/2025	122	-15	-9	10	7
12/31/2024	109	-26	-20	1	6
3/31/2024	137	-63	-22	-14	N/A
12/31/2023	143	-66	-24	-12	N/A
9/30/2023	155	-102	-22	-7	N/A
6/30/2023	162	-83	-17	-1	N/A
3/31/2023	163	-146	-19	-3	N/A
12/31/2022	162	-140	-22	-8	N/A
9/30/2022	155	-106	-28	-17	N/A
6/30/2022	148	-96	-27	-17	N/A
3/31/2022	139	-15	-27	-14	N/A
12/31/2021	119	-9	-19	-5	N/A
9/30/2021	97	5	-19	-2	N/A
6/30/2021	74	4	-19	-4	N/A
3/31/2021	53	-20	-3	8	N/A
12/31/2020	48	2	-1	7	N/A
9/30/2020	42	7	0	3	N/A
6/30/2020	37	16	1	5	N/A
3/31/2020	34	39	-3	1	N/A
12/31/2019	27	-2	-1	1	N/A
9/30/2019	25	-32	2	3	N/A
6/30/2019	23	-39	2	2	N/A
3/31/2019	22	-44	2	3	N/A
12/31/2018	20	-25	2	2	N/A
9/30/2018	17	1	2	3	N/A
6/30/2018	15	0	2	2	N/A
3/31/2018	12	-2	1	1	N/A
12/31/2017	11	-3	N/A	1	N/A
9/30/2017	10	-5	N/A	-1	N/A
6/30/2017	9	-6	N/A	-2	N/A
3/31/2017	9	-7	N/A	-3	N/A
12/31/2016	8	-7	N/A	-4	N/A
9/30/2016	8	-5	N/A	-5	N/A
6/30/2016	7	-5	N/A	-5	N/A
3/31/2016	7	-4	N/A	-5	N/A
12/31/2015	6	-4	N/A	-5	N/A
9/30/2015	6	-4	N/A	-4	N/A
6/30/2015	6	-4	N/A	-4	N/A
3/31/2015	6	-4	N/A	-4	N/A
12/31/2014	6	-3	N/A	-3	N/A
9/30/2014	7	-3	N/A	-2	N/A
6/30/2014	8	-2	N/A	-2	N/A
3/31/2014	9	-2	N/A	-1	N/A
12/31/2013	9	-1	N/A	0	N/A
9/30/2013	9	-1	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BLFS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: BLFS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: BLFS wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: BLFSDie Einnahmen des Unternehmens (14.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: BLFSDie Einnahmen des Unternehmens (14.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BLFS wird voraussichtlich in 3 Jahren unrentabel sein.

BioLife Solutions Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 47%

No longer forecast to breakeven

Price target increased by 7.8% to US$23.88

Forecast breakeven date pushed back to 2026

Forecast breakeven date pushed back to 2026

Consensus EPS estimates fall by 75%

Recent updates

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

BioLife Solutions, Inc., Annual General Meeting, Aug 01, 2024

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver

Consensus estimates of losses per share improve by 47%

No longer forecast to breakeven

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

Price target increased by 7.8% to US$23.88

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 1Q 2023)

BioLife Solutions, Inc. to Report Q1, 2024 Results on May 09, 2024

Forecast breakeven date pushed back to 2026

An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $2.6 million.

An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS).

Lead Director notifies of intention to sell stock

Lead Director recently sold US$190k worth of stock

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Full year 2023 earnings: EPS exceeds analyst expectations

Forecast breakeven date pushed back to 2026

BioLife Solutions, Inc. to Report Q4, 2023 Results on Feb 29, 2024

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Consensus EPS estimates fall by 75%

Third quarter 2023 earnings: EPS misses analyst expectations

BioLife Solutions, Inc. to Report Q3, 2023 Results on Nov 09, 2023

BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Consensus revenue estimates decrease by 18%, EPS upgraded

Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Price target decreased by 17% to US$25.14

BioLife Solutions, Inc. to Report Q2, 2023 Results on Aug 08, 2023

BioLife Solutions, Inc., Annual General Meeting, Jul 21, 2023

BioLife Solutions, Inc. announced delayed 10-Q filing

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Biolife Solutions, Inc. Reaffirms Earnings Guidance for the Fiscal 2023

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Chairman of Scientific Advisory Board exercised options and sold US$346k worth of stock

Chairman & CEO recently sold US$64k worth of stock

Chairman of Scientific Advisory Board exercised options and sold US$391k worth of stock

Consensus EPS estimates fall by 62%

Full year 2022 earnings: EPS misses analyst expectations

Chairman & CEO recently sold US$98k worth of stock

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Chairman of Scientific Advisory Board exercised options and sold US$436k worth of stock

Director recently sold US$88k worth of stock

Director recently sold US$88k worth of stock

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Chairman of Scientific Advisory Board exercised options and sold US$321k worth of stock

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Now 20% undervalued after recent price drop

Price target decreased to US$31.50

President & COO recently sold US$477k worth of stock

Price target decreased to US$31.50

BioLife Solutions, Inc. Updates Revenue Guidance of 2022

BioLife Solutions, Inc. to Report Q3, 2022 Results on Nov 09, 2022

BioLife: What The Future Holds

President & COO recently sold US$194k worth of stock

BioLife Solutions, Inc. Announces Executive Changes

BioLife Solutions COO Roderick de Greef to retire

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

Biolife Solutions Appoints Cell Therapy Executive Timothy L. Moore to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

BioLife Solutions, Inc. Provides Revenue Guidance for the Year 2022

BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M

BioLife Solutions, Inc. to Report Q2, 2022 Results on Aug 09, 2022